Pharmacokinetic-Pharmacodynamic Target Attainment Analysis to Support VL-2397 Dose Selection for a Phase 2 Trial in Patients with Invasive Aspergillosis
نویسندگان
چکیده
1514. Delayed Dosing of S-033188, a Novel Inhibitor of Influenza Virus Capdependent Endonuclease, Exhibited Significant Reduction of Viral Titer and Mortality in Mice Infected with Influenza A Virus Keita Fukao, MS; Yoshinori Ando, PhD; Takeshi Noshi, MS; Makoto Kawai, Ph. D.; Ryu Yoshida, Ph. D.; Takao Shishido, Ph. D. and Akira Naito, Ph. D. SHIONOGI & CO., LTD., Osaka, Japan, SHIONOGI & CO., LTD., Toyonaka, Japan
منابع مشابه
Population Pharmacokinetics of Isavuconazole from Phase 1 and Phase 3 (SECURE) Trials in Adults and Target Attainment in Patients with Invasive Infections Due to Aspergillus and Other Filamentous Fungi
Isavuconazole, the active moiety of the water-soluble prodrug isavuconazonium sulfate, is a triazole antifungal agent used for the treatment of invasive fungal infections. The objective of this analysis was to develop a population pharmacokinetic (PPK) model to identify covariates that affect isavuconazole pharmacokinetics and to determine the probability of target attainment (PTA) for invasive...
متن کاملPopulation Pharmacokinetic - Pharmacodynamic Analysis of Voriconazole and Anidulafungin in 1 Adult Patients with Invasive
Population Pharmacokinetic-Pharmacodynamic Analysis of Voriconazole and Anidulafungin in 1 Adult Patients with Invasive Aspergillosis 2 Ping Liu and Diane R. Mould 3 4 Clinical Pharmacology, Global Established Pharma Business, Pfizer Inc., Groton, CT, USA 5 Projections Research Inc., Phoenixville, PA, USA 6 7 8 Running title: Population PK-PD analysis of voriconazole and anidulafungin in IA pat...
متن کاملPharmacokinetics and Pharmacokinetic/Pharmacodynamic Modeling of Filgotinib (GLPG0634), a Selective JAK1 Inhibitor, in Support of Phase IIB Dose Selection
BACKGROUND AND OBJECTIVES Filgotinib (GLPG0634) is a selective inhibitor of Janus kinase 1 (JAK1) currently in development for the treatment of rheumatoid arthritis and Crohn's disease. While less selective JAK inhibitors have shown long-term efficacy in treating inflammatory conditions, this was accompanied by dose-limiting side effects. Here, we describe the pharmacokinetics of filgotinib and...
متن کاملIsavuconazole Population Pharmacokinetic Analysis Using Nonparametric Estimation in Patients with Invasive Fungal Disease (Results from the VITAL Study)
Isavuconazonium sulfate (Cresemba; Astellas Pharma Inc.), a water-soluble prodrug of the triazole antifungal agent isavuconazole, is available for the treatment of invasive aspergillosis (IA) and invasive mucormycosis. A population pharmacokinetic (PPK) model was constructed using nonparametric estimation to compare the pharmacokinetic (PK) behaviors of isavuconazole in patients treated in the ...
متن کاملUse of pharmacokinetic-pharmacodynamic target attainment analyses to support phase 2 and 3 dosing strategies for doripenem.
A doripenem population pharmacokinetic model and Monte Carlo simulations were utilized for dose regimen decision support for future clinical development. Simulation results predict that 500 mg of doripenem administered over 1 h every 8 h would be effective against bacterial strains with MICs less than 2 microg/ml and that less susceptible strains could be treated with prolonged infusions.
متن کامل